Selcis BioPharma is developing a technology where short-chain fatty acids (SCFAs) can be delivered to the colon.
Alexandra Ellervik has a M.Sc. in Molecular Biology and was awarded a PhD in neurophysiology in 2004 at Lund University. After two years as a postdoctoral fellow at the University of Zurich in Switzerland, she was employed within the private business as project manager, business developer and marketer and also elected as board member. Dr Ellervik is currently employed as project manager at RhoVac AB and joined Selcis BioPharma 2021.